Overview


According to FutureWise analysis the market for Influenza Vaccine in 2023 is US$ 7.79 billion, and is expected to reach US$ 13.44 billion by 2031 at a CAGR of 7.05%.

The viral infection that affects the respiratory system as a result of the illness is known as influenza. Respiratory droplets are the primary method of influenza virus transmission. Additionally, it can be spread verbally or physically through contact. Numerous regional epidemics and outbreaks caused by the influenza virus have killed thousands of people. Due to the influenza virus's changing properties, an annual adjustment of the vaccine strain is required to match the influenza virus strain. Healthcare organisations throughout the world, including the Centers for Disease Control and Prevention (CDC), have recommended vaccines like baloxavir marboxil (Xofluza) for the treatment of influenza. These vaccines can help patients with their flu symptoms. Three different influenza viruses are utilised in the flu vaccines: influenza type A with the H3N2 virus strain, influenza type A with the H1N1 virus strain, and influenza type B virus strain. The forecast period is likely to see increased product sales due to an increase in the frequency of influenza epidemics and seasonal outbreaks. One of the key drivers propelling the market's expansion is the expansion of government support and oversight of influenza vaccination on the local, national, and international levels to track the supply, distribution, and administration of flu vaccines. Additionally, the introduction of therapeutically effective vaccinations has been made possible by rising government funding as well as increased investment from top market players around the world, which is fueling the expansion of the influenza vaccine market. The urgent need for an effective influenza vaccine is being driven by the swift global spread of influenza virus epidemics. The main driver fueling the market's expansion throughout the projection period is a strong product pipeline.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Influenza Vaccine Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Influenza Vaccine Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Astrazeneca Plc (Astrazeneca)
  • Biodiem
  • Csl Limited (Seqirus Gmbh)
  • Emergent Biosolutions
  • F. Hoffmann-la Roche Ltd.
  • Gamma Vaccines Pty Ltd.
  • Glaxosmithkline Plc
  • Merckco., Inc. (Merck Sharp
  • Dohme Corp.)
  • Novartis Ag
  • Pfizer Inc.
  • Sanofi
  • Sinovac Biotech Ltd.
  • Abbott Laboratories
  • Siemens Healthcare

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Vaccine Type

  • Quadrivalent
  • Trivalent

By Type

  • Seasonal
  • Pandemic

By Technology

  • Egg-based
  • Cell-based

By Age Group

  • Pediatric
  • Adult

By Route of Administration

  • Injection
  • Nasal Spray

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa


  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Influenza Vaccine Market By Vaccine Type, By Type, By Technology, By Age Group, By Route of Administration and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Influenza Vaccine Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Influenza Vaccine Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Influenza Vaccine Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Influenza Vaccine Market, By Vaccine Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Quadrivalent
        2. Trivalent

  • 8.   Influenza Vaccine Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Seasonal
        2. Pandemic

  • 9.   Influenza Vaccine Market, By Technology Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Egg-based
        2. Cell-based

  • 10.   Influenza Vaccine Market, By Age Group Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Pediatric
        2. Adult

  • 11.   Influenza Vaccine Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Injection
        2. Nasal Spray

  • 12.   North America Influenza Vaccine Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 13.   Latin America Influenza Vaccine Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 14.   Europe Influenza Vaccine Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 15.   Asia Pacific Influenza Vaccine Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 16.   Middle East and Africa Influenza Vaccine Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 17.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 18.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Astrazeneca Plc (Astrazeneca)
                1.1. Company Overview
                1.2. Product Portfolio
                1.3. SWOT Analysis
                1.4. Financial Overview
                1.5. Strategic Overview
        2. Biodiem
                2.1. Company Overview
                2.2. Product Portfolio
                2.3. SWOT Analysis
                2.4. Financial Overview
                2.5. Strategic Overview 
        3. Csl Limited (Seqirus Gmbh)
                3.1. Company Overview
                3.2. Product Portfolio
                3.3. SWOT Analysis
                3.4. Financial Overview
                3.5. Strategic Overview
        4. Emergent Biosolutions
                4.1. Company Overview
                4.2. Product Portfolio
                4.3. SWOT Analysis
                4.4. Financial Overview
                4.5. Strategic Overview
        5. F. Hoffmann-la Roche Ltd.
                5.1. Company Overview
                5.2. Product Portfolio
                5.3. SWOT Analysis
                5.4. Financial Overview
                5.5. Strategic Overview          
        6. Gamma Vaccines Pty Ltd.
                6.1. Company Overview
                6.2. Product Portfolio
                6.3. SWOT Analysis
                6.4. Financial Overview
                6.5. Strategic Overview
        7. Glaxosmithkline Plc
                7.1. Company Overview
                7.2. Product Portfolio
                7.3. SWOT Analysis
                7.4. Financial Overview
                7.5. Strategic Overview
        8. Merck & Co. Inc. (Merck Sharp & Dohme Corp.)
                8.1. Company Overview
                8.2. Product Portfolio
                8.3. SWOT Analysis
                8.4. Financial Overview
                8.5. Strategic Overview
        9. Novartis Ag
                9.1. Company Overview
                9.2. Product Portfolio
                9.3. SWOT Analysis
                9.4. Financial Overview
                9.5. Strategic Overview          
        10. Pfizer Inc.
                10.1. Company Overview
                10.2. Product Portfolio
                10.3. SWOT Analysis
                10.4. Financial Overview
                10.5. Strategic Overview
        11. Sanofi
                11.1. Company Overview
                11.2. Product Portfolio
                11.3. SWOT Analysis
                11.4. Financial Overview
                11.5. Strategic Overview          
        12. Sinovac Biotech Ltd.
                12.1. Company Overview
                12.2. Product Portfolio
                12.3. SWOT Analysis
                12.4. Financial Overview
                12.5. Strategic Overview
        13. Abbott Laboratories
                13.1. Company Overview
                13.2. Product Portfolio
                13.3. SWOT Analysis
                13.4. Financial Overview
                13.5. Strategic Overview          
        14. Siemens Healthcare
                14.1. Company Overview
                14.2. Product Portfolio
                14.3. SWOT Analysis
                14.4. Financial Overview
                14.5. Strategic Overview

  • 19.  Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 20.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients